issued a statement following announcement from Pfizer and Medivation that their investigational Alzheimer’s medication Dimebon did not meet either its co-principal or secondary endpoints in comparison to placebo during pivotal Phase 3 scientific trials. ‘While this is disappointing for the Alzheimer’s community, there have been many doubts expressed about Dimebon. These doubts have been documented by leading researchers, including ex-Nationwide Institutes of Wellness staffers. This failing of Dimebon, which was hypothesized to do something as a mitochondrial pore blocker, along with the repeated failures of each medication studied for getting rid of beta amyloid from the brain as a way to manage Alzheimer’s disease, shows that novel mechanisms of actions that attempt to modify the disease itself, rather than treat symptoms, are necessary,’ said Cameron Durrant, MD, MBA, Executive Chairman of the ANAVEX Plank of Directors.Changes in transaminase, low-density lipoprotein elevations, and neutrophil reductions occurred in both hands, with the proportion of patients with abnormal ideals higher in the tocilizumab arm. There were two deaths reported in the tocilizumab arm; one from sudden death and one from illicit medication reports .com writes. Relating to a U.N. Discharge, ALMA may be the brainchild of Tanzanian President Jakaya Kikwete and Ray Chambers, the U.N. Secretary-general’s unique envoy for malaria.N. General Assembly meeting . This article is certainly republished with kind permission from our friends at The Kaiser Family members Foundation. You will see the entire Kaiser Daily Health Plan Report, search the archives, or join email delivery of in-depth coverage of health policy developments, discussions and debates.